Bacci Christian, Cerrato Alessia, Dotto Virginia, Zambello Renato, Barilà Gregorio, Liço Albana, Semenzato Gianpietro, Stellini Edoardo, Zanette Gastone
Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.
Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.
Dent J (Basel). 2021 Jan 20;9(2):11. doi: 10.3390/dj9020011.
(1) Background: Multiple myeloma is a rare cancer that primarily affects the bone marrow. Osteoclasts are responsible for increased bone resorption and, therefore, bone destruction. Bisphosphonates are a class of drugs that can slow down bone resorption by reducing the number and action of osteoclasts. Intravenous injections of bisphosphonates (generally Zoledronic Acid) are administered to patients affected by Multiple Myeloma, but BRONJ is described as a serious side effect. This 5-year retrospective study aims to evaluate the efficacy of appropriate dental treatment protocols prior to initiating bisphosphonate therapy to prevent the development of BRONJ. (2) Methods: A total of 99 patients with symptomatic multiple myeloma were involved in this study (41-90 years, mean age 65 years, standard deviation 5 years). The data relating to the visits were tracked using a specific server and consulting the clinical reports. The AAOMS (American Association of Oral and Maxillofacial Surgeons) position was applied for both diagnosis and treatment. A total of 79 patients were examined before the administration of bisphosphonates (group A) and 20 after (group B). (3) Results: The entire sample required dental treatment: 23.2% underwent restorative therapy, 8% endodontic treatments, 44.4% tooth extractions. Periodontal disease was present in 41.4% of the patients. No osteonecrosis was observed in the first group, whereas BRONJ was found in five patients of the second one (25%) and two patients (10%) showed osteosclerotic areas under investigation [OR 0.026 (CI 0.0027 to 0.2454)]. (4) Conclusions: In the literature, there are no precise data about the prevalence of BRONJ. Despite the limitation of the present study, we point out that dental treatment before the treatment with intravenous bisphosphonates can help in reducing the incidence of BRONJ and good dental status is necessary for BRONJ prevention.
(1) 背景:多发性骨髓瘤是一种主要影响骨髓的罕见癌症。破骨细胞会导致骨吸收增加,进而造成骨质破坏。双膦酸盐类药物是一类能够通过减少破骨细胞数量及活性来减缓骨吸收的药物。多发性骨髓瘤患者会接受双膦酸盐类药物的静脉注射(通常为唑来膦酸),但颌骨坏死性骨炎(BRONJ)被描述为一种严重的副作用。这项为期5年的回顾性研究旨在评估在开始双膦酸盐治疗前采用适当的牙科治疗方案预防BRONJ发生的疗效。(2) 方法:本研究共纳入99例有症状的多发性骨髓瘤患者(年龄41 - 90岁,平均年龄65岁,标准差5岁)。使用特定服务器并查阅临床报告来跟踪与就诊相关的数据。诊断和治疗均采用美国口腔颌面外科医师协会(AAOMS)的立场。共有79例患者在使用双膦酸盐前接受检查(A组),20例在使用后接受检查(B组)。(3) 结果:整个样本都需要牙科治疗:23.2%接受了修复治疗,8%接受了牙髓治疗,44.4%接受了拔牙。41.4%的患者存在牙周疾病。第一组未观察到骨坏死,而第二组有5例患者出现BRONJ(25%),2例患者(10%)在研究中有骨硬化区域[比值比0.026(可信区间0.0027至0.2454)]。(4) 结论:在文献中,关于BRONJ患病率没有确切数据。尽管本研究存在局限性,但我们指出在静脉注射双膦酸盐治疗前进行牙科治疗有助于降低BRONJ的发生率,良好的口腔状况对于预防BRONJ是必要的。